番茄社区

According to a phase III study presented at the recent American Society of Clinical Oncology (ASCO) meeting, subcutaneous amivantamab (Rybrevant) was noninferior to intravenous amivantamab for pretreated advanced EGFR-mutated non-small cell lung cancer (NSCLC). The subcutaneous formulation could potentially offer a better dosing experience for patients and surprisingly was associated with better oncologic outcomes in the study.

In this exclusive 番茄社区 video, Jorge Nieva, MD, from the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the PALOMA-3 trial.

Following is a transcript of his remarks:

One of the exciting things about the abstract comparing subcutaneous to intravenous amivantamab for the treatment of patients with EGFR-mutated lung cancer is really what a victory it is for patients. We're talking about a new formulation of the medicine that now means that what used to be a 5-hour infusion is now a 5-minute infusion.

And one of the other great things about this finding was that the impact of the change on overall survival, progression-free survival, and response was actually favorable in favor of the subcutaneous formulation.

Of course, there were no large differences between the two drugs because it's the same medicine underlying it, but it's great to see that we have something that has a much lower incidence of infusion-related reactions.

I think this abstract goes along well with the meeting that we really want to take care of the whole patient and we really want to have care that's patient-centered. And this formulation change for this medication really means that our patients are going to get care that is easier, care that has less toxicity, and I think that's something that we really want for all of our medications. It's great to see more and more monoclonal antibodies now being available in this new formulation.

The subcutaneous version of the medication is not yet commercially available, but we anticipate that based on the results of this trial, it should be commercially available soon, and once it is, it makes sense for patients to fairly rapidly change over to this new formulation because it really does appear to be superior in most ways.

Comment